# Scemblix

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/scemblix
Canonical HTML page: https://gethealthbrief.com/entity/scemblix

## Timeline

- **2028**: Keytruda Patent Cliff — Merck faces the loss of exclusivity for its top-selling cancer immunotherapy.
- **2026**: Expected Closing — Anticipated completion of the acquisition following regulatory reviews.
- **2026-03-25**: Acquisition Announcement — Merck announces definitive agreement to buy Terns for $6.7 billion.
- **2024**: Clinical Progress — Terns Pharmaceuticals advances TERN-701 through early-stage clinical trials for CML.

## Recent coverage (1 stories)

### Merck Bolsters Oncology Pipeline with $6.7B Acquisition of Terns Pharmaceuticals
2026-03-25 19:17:39 · Sentiment: Positive · Impact: 8/10 · Sources: 2

Merck has reached a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising Phase 2 leukemia treatment. The cash deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Full story: https://gethealthbrief.com/story/merck-acquires-terns-pharmaceuticals-leukemia-deal

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.